Berit Feiring

Summary

Affiliation: Norwegian Institute of Public Health
Country: Norway

Publications

  1. pmc Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine
    Berit Feiring
    Division of Infectious Disease Control, Norwegian Institute of Public Health NIPH, P O Box 4404, Nydalen, N 0403 Oslo, Norway
    Clin Vaccine Immunol 13:790-6. 2006
  2. pmc Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
    Bernardo Rafael Guzmán Herrador
    Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway
    BMC Infect Dis 12:63. 2012
  3. pmc Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines
    Synne Sandbu
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, NO 0403 Oslo, Norway
    Clin Vaccine Immunol 14:1062-9. 2007
  4. pmc Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic
    Ingeborg S Aaberge
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, NO 0403 Oslo, Norway
    Clin Diagn Lab Immunol 12:599-605. 2005

Collaborators

  • Ingeborg S Aaberge
  • Bernardo Rafael Guzmán Herrador
  • Synne Sandbu
  • Oddveig S Helland
  • Philipp Oster
  • Anne Cathrine Kristoffersen
  • Hanne Nøkleby
  • Katrine Borgen
  • Preben Aavitsland
  • Marianne A Riise Bergsaker
  • Hilde S W Bakke
  • Sandrine Tilman
  • Kjersti M Rydland
  • Einar Rosenqvist
  • Audun Aase
  • Lisbeth M Naess
  • E Arne Høiby
  • Ellen Ypma

Detail Information

Publications4

  1. pmc Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine
    Berit Feiring
    Division of Infectious Disease Control, Norwegian Institute of Public Health NIPH, P O Box 4404, Nydalen, N 0403 Oslo, Norway
    Clin Vaccine Immunol 13:790-6. 2006
    ..This study confirmed the good immunogenicity of the primary course of MenBvac and demonstrated prolonged persistence and increased cross-reactivity of functional antibodies elicited by a booster dose...
  2. pmc Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
    Bernardo Rafael Guzmán Herrador
    Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway
    BMC Infect Dis 12:63. 2012
    ..Based on these registries, we aimed at estimating the vaccine effectiveness (VE) and describing vaccine failures during the pandemic in Norway, in order to evaluate the role of the vaccine as a preventive measure during the pandemic...
  3. pmc Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines
    Synne Sandbu
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, NO 0403 Oslo, Norway
    Clin Vaccine Immunol 14:1062-9. 2007
    ..In conclusion, use of either of the single vaccines or the combination of MenBvac and MeNZB may have a considerable impact on the serogroup B meningococcal disease situation in many countries...
  4. pmc Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic
    Ingeborg S Aaberge
    Division of Infectious Disease Control, Norwegian Institute of Public Health, P O Box 4404 Nydalen, NO 0403 Oslo, Norway
    Clin Diagn Lab Immunol 12:599-605. 2005
    ..The induced immune responses suggest that the combined vaccine is likely to confer protection against systemic group B disease caused by the vaccine strain as well as against group C meningococcal disease...